Thor Medical Enters into an Agreement with Node Pharma for Supply of Radium-224 and Lead-212

Norway, March 31 -- Thor Medical, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, has entered into a multiyear frame agreement with Node Pharma, a Norwegian radiopharmaceutical company, for the supply of radium-224 (Ra-224) and lead-212 (Pb-212) for preclinical use.The agreement follows successful product sample deliveries from Thor Medical's pilot facility at Heroya Industrial Park to Node Pharma and supports further expansion of Node Pharma's development pipeline for alpha-emitting therapies. Radium-224 and lead-212, together with thorium-228, are part of Thor Medical's portfolio of products.

Published by HT Digital Content Services with permission from Pivotal Sources....